Ligand Pharmaceuticals, Inc. - Ordinary Shares - Class B

NASDAQ:LGND  
130.51
+4.03 (+3.19%)
Mergers / Acquisitions

Ligand Acquires xCella, Taurus Biosciences

Published: 09/10/2020 12:40 GMT
Ligand Pharmaceuticals, Inc. - Ordinary Shares - Class B (LGND) - Ligand Expands Omniab Antibody Discovery Platform Through Acquisitions of Xcella Biosciences and Taurus Biosciences.
Ligand Pharmaceuticals Inc - Acquired Xcella Biosciences, Inc. for $7 Million in Cash Plus Potential Earnouts.
Ligand Pharmaceuticals Inc - Acquired Taurus Biosciences Llc for $5 Million in Cash Plus Non-transferable Contingent Value Rights.
Ligand Pharmaceuticals Inc - Will Invest $2.5 Million in a New Company, Minotaur Therapeutics, Which Will Be Led by Taurus Biosciences' Founder.